Delving into the Latest Updates on Hangzhou RonGu Biotechnology Co., Ltd. with Synapse

Overview

Tags

Neoplasms

Immune System Diseases

Hemic and Lymphatic Diseases

CAR-NK

CAR-T

Nanobody

Disease domain score

A glimpse into the focused therapeutic areas

Technology Platform

Most used technologies in drug development

Targets

Most frequently developed targets

Disease Domain	Count

Neoplasms	10
Hemic and Lymphatic Diseases	6
Immune System Diseases	6
Infectious Diseases	2
Endocrinology and Metabolic Disease	1

Top 5 Drug Type	Count

CAR-NK	5
CAR-T	2
Nanobody	2
Oncolytic virus	1

Top 5 Target	Count

CLDN18.2(Claudin 18.2)	2
CD19(B-lymphocyte antigen CD19)	2
CD70(CD70 antigen)	2
BCMA x CD19	1
CD19 x CD3	1

Main Objective: To study the maximum tolerated dose (MTD) and dose-dependent toxicity (DLT) of cord blood-derived CAR-NK cells (CB CAR-NK182) targeting Claudin18.2 in patients with advanced gastric cancer and advanced pancreatic cancer.
Secondary Objective: To evaluate the efficacy of CB CAR-NK182 in patients with advanced gastric cancer and advanced pancreatic cancer: overall objective tumor response rate (ORR), disease control rate (DCR), progression-free survival (PFS), overall survival (OS), duration of response (DOR), etc.
To evaluate the CAR-NK amplification and persistence of CB CAR-NK182 in the blood of patients with advanced gastric cancer and advanced pancreatic cancer;

Start Date19 Jul 2024

Sponsor / Collaborator

Zhejiang Provincial Peoples Hospital

[+2]

NCT04887025

/ RecruitingPhase 1IIT

Exploratory Study of a Novel Oncolytic Vaccinia Virus Expressing Bispecific Antibody in the Treatment of Refractory/Relapsed B-cell Lymphoma

This is a dose-escalation, single-arm, single-center open study which aims to evaluate the maximum tolerated dose (MTD) and dose-dependent toxicity (DLT) of a novel oncolytic vaccinia virus expressing bispecific antibody RGV004 in patients with relapsed/refractory B-cell lymphoma,

Start Date08 Feb 2022

Sponsor / Collaborator

Second Affiliated Hospital Zhejiang University College of

[+1]

100 Clinical Results associated with Hangzhou RonGu Biotechnology Co., Ltd.

Login to view more data

0 Patents (Medical) associated with Hangzhou RonGu Biotechnology Co., Ltd.

Login to view more data

100 Deals associated with Hangzhou RonGu Biotechnology Co., Ltd.

Login to view more data

100 Translational Medicine associated with Hangzhou RonGu Biotechnology Co., Ltd.

Login to view more data

Corporation Tree

Boost your research with our corporation tree data.

login

or

view full example data

Boost your research with our corporation tree data.

Pipeline

Pipeline Snapshot as of 03 May 2025

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3

Discovery

2

7

Preclinical

Phase 1 Clinical

1

2

Other

Login to view more data

Current Projects

Drug(Targets)	Indications	Global Highest Phase

RGV-004 ( CD19 x CD3 )	B-cell lymphoma refractory More	Phase 1
RG-70 ( CD70 )	T-Cell Lymphoma More	Preclinical
RG-BCMA ( BCMA )	Bone Marrow Neoplasms More	Preclinical
RG-1970 ( CD19 x CD70 )	Non-Hodgkin Lymphoma More	Preclinical
RG-019 ( CD19 )	Non-Hodgkin Lymphoma More	Preclinical